1620 Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History

1620 Investment Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$168K	Buy	997 +210	+27%	+$31.2K	0.1%	198
2026 Q1	$104K	Sell	787 -125	-14%	-$16.6K	0.07%	231
2025 Q4	$129K	Buy	912 +1	+0.1%	+$145	0.09%	203
2025 Q3	$128K	Sell	911 -13	-1%	-$1.76K	0.09%	197
2025 Q2	$116K	Sell	924 -3	-0.3%	-$344	0.08%	211
2025 Q1	$103K	Sell	927 -6	-0.6%	-$760	0.08%	210
2024 Q4	$127K	Buy	933 +66	+8%	+$8.16K	0.1%	190
2024 Q3	$99.9K	Buy	867 +10	+1%	+$1.37K	0.07%	225
2024 Q2	$118K	Buy	+857	New	+$118K	0.09%	199

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

1620 Investment Advisors's NBIX Position: Q2 2026 in Review

1620 Investment Advisors increased its Neurocrine Biosciences (NBIX) stake by 27% in Q2 2026, buying an estimated $31.2K and bringing the position to 997 shares worth $168K. The position accounts for 0.1% of the portfolio, ranked #198.

1620 Investment Advisors first reported a position in NBIX in Q2 2024 and has held it in 9 quarters since. 166 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

1620 Investment Advisors held 997 shares of Neurocrine Biosciences worth $168K as of Q2 2026.
1620 Investment Advisors bought 210 Neurocrine Biosciences shares in Q2 2026, an estimated $31.2K.
Neurocrine Biosciences made up 0.1% of 1620 Investment Advisors's portfolio in Q2 2026, its #198 holding.
1620 Investment Advisors first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 9 quarters since.
166 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on 1620 Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.